Bavarian Nordic A/S

BAVA

DK0015998017

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 06:46:07 26/06/2024 pm IST			5-day change	1st Jan Change
177.4 ^DKK	+13.71%		+13.69%	+1.35%

11:58am	Bavarian Nordic Files EU Application for Chikungunya Vaccine Candidate	MT
10:26am	Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema	CI

Bavarian Nordic A/S : Bavarian Nordic Announces Changes in Management

January 22, 2013 at 02:02 am IST

MarketScreener.com By

KVISTGAARD, Denmark, January 21, 2013 - Bavarian Nordic A/S (OMX: BAVA) today announced that Reiner Laus, Executive Vice President and Division President Cancer Vaccines will leave his position effective as of today.

Reiner Laus has headed Bavarian Nordic's California-based cancer vaccine division, BN ImmunoTherapeutics since 2005, where it was founded to develop active immunotherapies within the cancer field based on the company's MVA-BN® technology. During his tenure, Dr. Laus has been instrumental in the development of the company's clinical pipeline, including the preparations for the current late-stage clinical development of PROSTVAC®. The company has initiated a search for a replacement to fill his position which is expected to be concluded soon.

Contact:

Anders Hedegaard, President & CEO.
Phone: +45 23 20 30 64

distributed by

Latest news about Bavarian Nordic A/S

Bavarian Nordic Files EU Application for Chikungunya Vaccine Candidate	03:28pm	MT
Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema	01:56pm	CI
Bavarian Nordic Wraps Up US FDA's Biologics License Application for Chikungunya Vaccine Candidate	18/06	MT
High-risk health workers can get routine Ebola vaccine, Gavi says	13/06	RE
High-risk health workers can get routine Ebola vaccine, says Gavi	13/06	RE
Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	31/05	MT
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	30/05	MT
Bavarian Nordic A/S and Coalition for Epidemic Preparedness Innovations Partners to Advance Mpox Vaccination in Africa	30/05	CI
Bavarian Nordic’s Medical Chief to Step Down by May-end	21/05	MT
Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer	21/05	CI
Transcript : Bavarian Nordic A/S, Q1 2024 Earnings Call, May 08, 2024	08/05
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.	08/05	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024	08/05	CI
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine	30/04	MT
Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve	30/04	CI
Bavarian Nordic Starts US Rolling Submission Process for Chikungunya Vaccine Candidate	29/04	MT
Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate	29/04	CI
Bavarian Nordic A/S's Equity Buyback announced on May 9, 2023, has expired.	16/04	CI
Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	13/03	MT
Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	13/03	CI
Nordic Shares Moved Upward Wednesday; BoneSupport Holding Topped Leaders	06/03	DJ
Transcript : Bavarian Nordic A/S, 2023 Earnings Call, Mar 06, 2024	06/03
Bavarian Nordic A/S Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Bavarian Nordic A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03	CI

Chart Bavarian Nordic A/S

Duration

Period

More charts

Company Profile

Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%). Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bavarian Nordic A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

156 DKK

Average target price

263.2 DKK

Spread / Average Target

+68.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAVARIAN NORDIC A/S	+1.35%	1.74B
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+45.42%	654B
JOHNSON & JOHNSON	-6.09%	354B
MERCK & CO., INC.	+21.92%	337B
ABBVIE INC.	+10.18%	302B
ASTRAZENECA PLC	+18.18%	247B
ROCHE HOLDING AG	+2.25%	229B
NOVARTIS AG	+13.17%	219B
AMGEN INC.	+10.86%	171B

Other Pharmaceuticals